Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Unichem Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹293.55Overvalued by 42.44%vs CMP ₹510.00

P/E (29.4) × ROE (3.2%) × BV (₹386.00) × DY (2.00%)

₹496.01Fairly Valued by 2.74%vs CMP ₹510.00
MoS: -2.8% (Negative)Confidence: 48/100 (Moderate)Models: 2 Under, 1 Fair, 5 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹454.6427%Over (-10.9%)
Graham NumberEarnings₹603.1016%Under (+18.3%)
DCFCash Flow₹957.4213%Under (+87.7%)
Net Asset ValueAssets₹386.099%Over (-24.3%)
EV/EBITDAEnterprise₹483.1411%Fair (-5.3%)
Earnings YieldEarnings₹418.809%Over (-17.9%)
ROCE CapitalReturns₹82.679%Over (-83.8%)
Revenue MultipleRevenue₹299.977%Over (-41.2%)
Consensus (8 models)₹496.01100%Fairly Valued
Key Drivers: EPS CAGR 54.9% lifts DCF — verify sustainability. | ROE 3.2% is below cost of equity.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 54.9%

*Investments are subject to market risks

Analyst Summary

Unichem Laboratories Ltd operates in the Pharmaceuticals segment, current market price is ₹510.00, market cap is 3,589 Cr.. At a glance, stock P/E is 29.4, ROE is 3.17 %, ROCE is 4.13 %, book value is 386, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹496.01, which is broadly in line with the current market price. On operating trend, latest reported sales are about ₹2,111 Cr versus the prior period change of 18.3%, while latest net profit is about ₹138 Cr with a prior-period change of 246.8%. The 52-week range shown on this page is 687/278, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisUnichem Laboratories Ltd. is a Public Limited Listed company incorporated on 22/08/1962 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN)…

This summary is generated from the stock page data available for Unichem Laboratories Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

52
Unichem Laboratories Ltd scores 52/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health54/100 · Moderate
ROCE 4.1% WeakROE 3.2% WeakD/E 0.03 Low debtInterest Coverage 0.0x RiskyProfitable 3/5 years Mixed
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 70.2% Stable
Earnings Quality55/100 · Moderate
OPM expanding (2% → 9%) ImprovingWorking capital: 159 days Capital intensive
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +13% YoY GrowingOPM: 9.0% (down 7.0% YoY) Margin pressure
Industry Rank45/100 · Moderate
P/E 29.4 vs industry 54.6 Cheaper than peersROCE 4.1% vs industry 25.3% Below peersROE 3.2% vs industry 18.4% Below peers3Y sales CAGR: 18% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: August 25, 2026, 8:30 am

Market Cap 3,589 Cr.
Current Price 510
Intrinsic Value₹496.01
High / Low 687/278
Stock P/E29.4
Book Value 386
Dividend Yield0.00 %
ROCE4.13 %
ROE3.17 %
Face Value 2.00
PEG Ratio0.54

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Unichem Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Unichem Laboratories Ltd 3,589 Cr. 510 687/27829.4 3860.00 %4.13 %3.17 % 2.00
Kwality Pharmaceuticals Ltd 3,582 Cr. 3,452 3,744/82943.9 3210.00 %23.9 %22.5 % 10.0
Zota Health Care Ltd 3,791 Cr. 1,094 1,740/1,026 2000.09 %8.47 %15.0 % 10.0
Advanced Enzyme Technologies Ltd 3,386 Cr. 302 420/25221.5 1461.77 %14.0 %10.2 % 2.00
Aarti Drugs Limited 3,843 Cr. 421 535/31922.2 1540.48 %11.6 %12.7 % 10.0
Industry Average23,072.45 Cr1,307.3954.56215.820.36%25.34%18.37%6.02

All Competitor Stocks of Unichem Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 302402423416466432483507533587527579521
Expenses 345386395407435406443452448503504513476
Operating Profit -4316289312540558684226645
OPM % -14%4%7%2%7%6%8%11%16%14%4%11%9%
Other Income 16-289679-119491497-37287
Interest 4667654575787
Depreciation 31302929322732323130323131
Profit before tax -61-472-2273-1268276258-9-11293
Tax % 4%-6%132%12%-0%3%74%9%6%8%16%10%10%
Net Profit -64-44-1-2473-1292255853-10-12264
EPS in Rs -9.08-6.29-0.10-3.4810.40-18.370.293.508.227.52-1.49-1.6937.54

Last Updated: March 3, 2026, 2:02 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 7:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,1331,2021,3336988151,1801,1041,2351,2701,3431,7852,1112,214
Expenses 9561,1001,1697389421,2541,1531,1441,1981,3891,6981,8461,997
Operating Profit 178101164-41-128-74-499172-4687265217
OPM % 16%8%12%-6%-16%-6%-4%7%6%-3%5%13%10%
Other Income 8320151842,73591915047-0-2635266
Interest 33338885617232128
Depreciation 464139445167828491113123125124
Profit before tax 21277137972,548-58-485122-176-85155331
Tax % 20%3%21%-12%0%-59%25%33%-50%15%10%11%
Net Profit 169751081092,545-24-603433-202-94138295
EPS in Rs 18.688.3111.9011.96361.82-3.38-8.554.874.70-28.72-13.3219.5341.88
Dividend Payout % 43%24%17%25%1%-118%-47%82%85%-14%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-55.62%44.00%0.93%2234.86%-100.94%-150.00%156.67%-2.94%-712.12%53.47%246.81%
Change in YoY Net Profit Growth (%)0.00%99.62%-43.07%2233.94%-2335.81%-49.06%306.67%-159.61%-709.18%765.59%193.34%

Unichem Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:6%
5 Years:14%
3 Years:18%
TTM:20%
Compounded Profit Growth
10 Years:6%
5 Years:29%
3 Years:63%
TTM:651%
Stock Price CAGR
10 Years:7%
5 Years:15%
3 Years:12%
1 Year:-13%
Return on Equity
10 Years:12%
5 Years:0%
3 Years:-1%
Last Year:6%

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: July 27, 2026, 3:00 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 181818141414141414141414
Reserves 8499361,0452,6662,6062,5172,5432,6042,4212,4242,4372,703
Borrowings 223698151200206119349314248460500
Other Liabilities 264283359359323407436351444589659489
Total Liabilities 1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,707
Fixed Assets 4164034915788108708849901,2571,2521,3001,213
CWIP 1232372502389233056849414712331100
Investments 4114149019265503922642100
Other Assets 5746207661,4731,3131,3951,2691,5711,7871,8982,2392,394
Total Assets 1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,707

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + 7811268-112-3282033-260-8514-74
Cash from Investing Activity + -52-85-1321,648-286-36-6610024163-242194
Cash from Financing Activity + -51-3359-881-2-62-121191-81-1061842
Net Cash Flow -25-7-4655-616-78-1543275-29-65200
Free Cash Flow 4-28-79-271-519-360-254-386-1230-142163
CFO/OP 95%87%-237%89%424%-49%52%-350%160%23%4%6%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow178.0079.00128.00-139.00-279.00-274.00-255.00-28.00-277.00-360.00-161.00-195.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 63586016512413512974142160131135
Inventory Days 192171184397278278374518527414365418
Days Payable 142114131297230182236202161193174170
Cash Conversion Cycle 113116113265172231267390508382322382
Working Capital Days 948890174133165154163207207173159
ROCE %19%9%15%9%128%-2%-2%2%1%-5%-0%6%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters 70.21%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%70.22%
FIIs 0.83%0.84%0.90%0.89%0.94%1.05%0.98%0.98%0.99%0.99%1.00%0.90%
DIIs 10.00%10.46%11.26%11.57%11.65%11.63%11.32%10.92%10.74%10.73%10.63%10.46%
Public 18.95%18.47%17.63%17.32%17.17%17.11%17.47%17.88%18.04%18.05%18.14%18.41%
No. of Shareholders 21,58420,87721,17120,62120,37421,47221,62123,01023,57723,26723,38625,347

Shareholding Pattern Chart

No. of Shareholders

Unichem Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
DSP Healthcare Fund 852,063 1.06 33.24735,5912025-11-03 09:45:1515.83%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 19.53-10.01-28.724.704.88
Diluted EPS (Rs.) 19.53-10.01-28.724.704.88
Cash EPS (Rs.) 37.236.07-7.1317.8016.91
Book Value[Excl.RevalReserv]/Share (Rs.) 348.10335.54345.89371.90363.16
Book Value[Incl.RevalReserv]/Share (Rs.) 348.10335.54345.89371.90363.16
Revenue From Operations / Share (Rs.) 299.85242.15190.75180.36175.43
PBDIT / Share (Rs.) 42.6418.73-0.9917.0920.07
PBIT / Share (Rs.) 24.952.64-17.114.148.09
PBT / Share (Rs.) 21.96-8.76-19.573.277.36
Net Profit / Share (Rs.) 19.53-10.01-23.254.854.92
NP After MI And SOA / Share (Rs.) 19.53-10.01-28.724.704.88
PBDIT Margin (%) 14.227.73-0.529.4711.43
PBIT Margin (%) 8.311.09-8.972.294.61
PBT Margin (%) 7.32-3.61-10.261.814.19
Net Profit Margin (%) 6.51-4.13-12.182.682.80
NP After MI And SOA Margin (%) 6.51-4.13-15.052.602.77
Return on Networth / Equity (%) 5.61-2.98-8.301.261.34
Return on Capital Employeed (%) 6.810.75-4.711.052.17
Return On Assets (%) 3.85-2.22-6.330.991.09
Long Term Debt / Equity (X) 0.020.010.020.030.00
Total Debt / Equity (X) 0.170.090.120.120.03
Asset Turnover Ratio (%) 0.620.530.410.300.35
Current Ratio (X) 2.052.402.492.992.72
Quick Ratio (X) 1.061.401.511.901.66
Inventory Turnover Ratio (X) 2.491.120.860.871.15
Dividend Payout Ratio (NP) (%) 0.000.000.0085.1882.04
Dividend Payout Ratio (CP) (%) 0.000.000.0022.6623.72
Earning Retention Ratio (%) 0.000.000.0014.8217.96
Cash Earning Retention Ratio (%) 0.000.000.0077.3476.28
Interest Coverage Ratio (X) 14.275.82-0.4019.7027.60
Interest Coverage Ratio (Post Tax) (X) 7.540.43-8.456.597.77
Enterprise Value (Cr.) 5189.653504.162147.122049.282195.83
EV / Net Operating Revenue (X) 2.462.061.601.611.78
EV / EBITDA (X) 17.2926.58-304.9717.0315.54
MarketCap / Net Operating Revenue (X) 2.312.021.521.441.76
Retention Ratios (%) 0.000.000.0014.8117.95
Price / BV (X) 1.991.460.830.700.85
Price / Net Operating Revenue (X) 2.312.021.521.441.76
EarningsYield 0.02-0.02-0.090.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

[display_about_company_data title=”About the Company – Qualitative Analysis”]

FAQ

What is the intrinsic value of Unichem Laboratories Ltd and is it undervalued?

As of 01 September 2026, Unichem Laboratories Ltd's intrinsic value is ₹496.01, which is 2.74% lower than the current market price of ₹510.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (3.17 %), book value (₹386), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Unichem Laboratories Ltd?

Unichem Laboratories Ltd is trading at ₹510.00 as of 01 September 2026, with a FY2026-2027 high of ₹687 and low of ₹278. The stock is currently in the middle of its 52-week range. Market cap stands at ₹3,589 Cr..

How does Unichem Laboratories Ltd's P/E ratio compare to its industry?

Unichem Laboratories Ltd has a P/E ratio of 29.4, which is below the industry average of 54.56. This is broadly in line with or below the industry average.

Is Unichem Laboratories Ltd financially healthy?

Key indicators for Unichem Laboratories Ltd: ROCE of 4.13 % is on the lower side compared to the industry average of 25.34%; ROE of 3.17 % is below ideal levels (industry average: 18.37%). Dividend yield is 0.00 %.

Is Unichem Laboratories Ltd profitable and how is the profit trend?

Unichem Laboratories Ltd reported a net profit of ₹138 Cr in Mar 2025 on revenue of ₹2,111 Cr. Compared to ₹33 Cr in Mar 2022, the net profit shows an improving trend.

Does Unichem Laboratories Ltd pay dividends?

Unichem Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹510.00. The company is currently not paying meaningful dividends.

Last Updated: August 25, 2026, 8:30 am
Author: Getaka|Social: XLinkedIn
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Unichem Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports